Analyst Research Report Snapshot

Title:

ICO THERAPEUTICS - IDEAL STUDY MISSES PRIMARY ENDPOINT

Price:

$10.00

Provider:

Edison Investment Research

Date:

16 Jun 2014

Pages:

2

Type:

AcrobatPDF

Companies referenced:

ICO.V

Available for Immediate Download
Summary:

Top-line data from the iDEAL Phase II study with iCo-007 in diabetic macular edema (DME) did not show a benefit in visual acuity (VA) after eight months, either alone or in combination with Lucentis or laser photocoagulation (LP). Full 12-month data are due in Q414, but the ~80% share price decline on the results, leading to a negative EV, suggests low investor expectations for a turnaround or further development of iCo-007.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.